A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
A phase 3 trial of Docetaxel in gastric & gastro-oesophageal junction cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.
Overview
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer is a phase 3 interventional study registered as NCT06296706 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 630 participants planned, started 2024-02-27 and due to reach its primary completion in 2026-06-01. Interventions recorded: Docetaxel for injection (Albumin-bound) and Taxotere (docetaxel).
Similar pages
not linked directly; found by shared links- TrialKN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Shares CSPC Pharmaceutical Group, Docetaxel, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialSafety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Shares CSPC Pharmaceutical Group, Docetaxel, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Shares Docetaxel, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialClinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialPhase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialA Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialJMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
Shares CSPC Pharmaceutical Group and the tag pipeline.